1. Home
  2. BBNX vs KMDA Comparison

BBNX vs KMDA Comparison

Compare BBNX & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

N/A

Current Price

$18.08

Market Cap

493.1M

Sector

Health Care

ML Signal

N/A

Logo Kamada Ltd.

KMDA

Kamada Ltd.

N/A

Current Price

$7.26

Market Cap

460.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BBNX
KMDA
Founded
2015
1990
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.1M
460.3M
IPO Year
2025
2013

Fundamental Metrics

Financial Performance
Metric
BBNX
KMDA
Price
$18.08
$7.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
2
Target Price
$23.80
$14.00
AVG Volume (30 Days)
1.3M
59.6K
Earning Date
04-21-2026
05-13-2026
Dividend Yield
N/A
3.08%
EPS Growth
78.95
N/A
EPS
N/A
N/A
Revenue
$100,251,000.00
N/A
Revenue This Year
$34.90
$13.94
Revenue Next Year
$34.63
$9.84
P/E Ratio
N/A
$24.59
Revenue Growth
53.94
N/A
52 Week Low
$8.80
$6.50
52 Week High
$32.71
$9.35

Technical Indicators

Market Signals
Indicator
BBNX
KMDA
Relative Strength Index (RSI) 63.68 52.48
Support Level $9.34 $6.95
Resistance Level $18.20 $7.37
Average True Range (ATR) 1.31 0.18
MACD 0.31 0.01
Stochastic Oscillator 95.44 74.07

Price Performance

Historical Comparison
BBNX
KMDA

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Share on Social Networks: